p.81 抽出テキスト

400. Whitlock RP, Vincent J, Blackall MH, Hirsh J, Fremes S, Novick R, et al. Left atrial appendage occlusion study II (LAAOS II). Can J Cardiol 2013;29:1443–7. https://doi.org/ 10.1016/j.cjca.2013.06.015 401. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med 2021; 384:2081–91. https://doi.org/10.1056/NEJMoa2101897 402. Zhang S, Cui Y, Li J, Tian H, Yun Y, Zhou X, et al. Concomitant transcatheter occlusion versus thoracoscopic surgical clipping for left atrial appendage in patients undergoing ablation for atrial fibrillation: a meta-analysis. Front Cardiovasc Med 2022;9:970847. https://doi.org/10.3389/fcvm.2022.970847 403. van Laar C, Verberkmoes NJ, van Es HW, Lewalter T, Dunnington G, Stark S, et al. Thoracoscopic left atrial appendage clipping: a multicenter cohort analysis. JACC Clin Electrophysiol 2018;4:893–901. https://doi.org/10.1016/j.jacep.2018.03.009 404. Kiviniemi T, Bustamante-Munguira J, Olsson C, Jeppsson A, Halfwerk FR, Hartikainen J, et al. A randomized prospective multicenter trial for stroke prevention by prophylactic surgical closure of the left atrial appendage in patients undergoing bioprosthetic aortic valve surgery–LAA-CLOSURE trial protocol. Am Heart J 2021;237:127–34. https://doi. org/10.1016/j.ahj.2021.03.014 405. Cartledge R, Suwalski G, Witkowska A, Gottlieb G, Cioci A, Chidiac G, et al. Standalone epicardial left atrial appendage exclusion for thromboembolism prevention in atrial fibrillation. Interact Cardiovasc Thorac Surg 2022;34:548–55. https://doi.org/10. 1093/icvts/ivab334 406. Branzoli S, Guarracini F, Marini M, D’Onghia G, Penzo D, Piffer S, et al. Heart team for left atrial appendage occlusion: a patient-tailored approach. J Clin Med 2022;11:176. https://doi.org/10.3390/jcm11010176 407. Toale C, Fitzmaurice GJ, Eaton D, Lyne J, Redmond KC. Outcomes of left atrial appendage occlusion using the AtriClip device: a systematic review. Interact Cardiovasc Thorac Surg 2019;29:655–62. https://doi.org/10.1093/icvts/ivz156 408. Caliskan E, Sahin A, Yilmaz M, Seifert B, Hinzpeter R, Alkadhi H, et al. Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery. Europace 2018;20:e105–14. https://doi. org/10.1093/europace/eux211 409. Nso N, Nassar M, Zirkiyeva M, Lakhdar S, Shaukat T, Guzman L, et al. Outcomes of cardiac surgery with left atrial appendage occlusion versus no occlusion, direct oral anticoagulants, and vitamin K antagonists: a systematic review with meta-analysis. Int J Cardiol Heart Vasc 2022;40:100998. https://doi.org/10.1016/j.ijcha.2022.100998 410. Ibrahim AM, Tandan N, Koester C, Al-Akchar M, Bhandari B, Botchway A, et al. Meta-analysis evaluating outcomes of surgical left atrial appendage occlusion during cardiac surgery. Am J Cardiol 2019;124:1218–25. https://doi.org/10.1016/j.amjcard. 2019.07.032 411. Park-Hansen J, Holme SJV, Irmukhamedov A, Carranza CL, Greve AM, Al-Farra G, et al. Adding left atrial appendage closure to open heart surgery provides protection from ischemic brain injury six years after surgery independently of atrial fibrillation history: the LAACS randomized study. J Cardiothorac Surg 2018;13:53. https://doi.org/10. 1186/s13019-018-0740-7 412. Soltesz EG, Dewan KC, Anderson LH, Ferguson MA, Gillinov AM. Improved outcomes in CABG patients with atrial fibrillation associated with surgical left atrial appendage exclusion. J Card Surg 2021;36:1201–8. https://doi.org/10.1111/jocs.15335 413. Fu M, Qin Z, Zheng S, Li Y, Yang S, Zhao Y, et al. Thoracoscopic left atrial appendage occlusion for stroke prevention compared with long-term warfarin therapy in patients with nonvalvular atrial fibrillation. Am J Cardiol 2019;123:50–6. https://doi.org/10.1016/ j.amjcard.2018.09.025 414. Peterson D, Geison E. Pharmacist interventions to reduce modifiable bleeding risk factors using HAS-BLED in patients taking warfarin. Fed Pract 2017;34:S16–20. 415. Chao TF, Lip GYH, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Incident risk factors and major bleeding in patients with atrial fibrillation treated with oral anticoagulants: a comparison of baseline, follow-up and Delta HAS-BLED scores with an approach focused on modifiable bleeding risk factors. Thromb Haemost 2018;47:768–77. https://doi.org/ 10.1055/s-0038-1636534 416. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003;139:893–900. https://doi.org/10.7326/0003-4819-139-11-200312020-00007 417. Kirchhof P, Haas S, Amarenco P, Hess S, Lambelet M, van Eickels M, et al. Impact of modifiable bleeding risk factors on major bleeding in patients with atrial fibrillation anticoagulated with rivaroxaban. J Am Heart Assoc 2020;9:e009530. https://doi.org/10. 1161/JAHA.118.009530 418. Guo Y, Lane DA, Chen Y, Lip GYH; mAF-App II Trial investigators. Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial. Am J Med 2020;133:1195–1202.e2. https://doi.org/10.1016/j.amjmed.2020. 03.019 419. Lane DA, Lip GYH. Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal. Eur Heart J Suppl 2020;22:O14–27. https://doi.org/10.1093/eurheartj/ suaa178 420. Lip GYH, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost 2016;14:1711–4. https://doi. org/10.1111/jth.13386 421. Gorog DA, Gue YX, Chao TF, Fauchier L, Ferreiro JL, Huber K, et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: a position paper from the ESC working group on thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Europace 2022;24:1844–71. https://doi.org/10. 1093/europace/euac020 422. Nelson WW, Laliberté F, Patel AA, Germain G, Pilon D, McCormick N, et al. Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk. Curr Med Res Opin 2017;33:631–8. https://doi.org/10.1080/03007995.2016.1275936 423. Hijazi Z, Lindbäck J, Oldgren J, Benz AP, Alexander JH, Connolly SJ, et al. Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores. Am Heart J 2023;261:55–63. https://doi.org/10.1016/j.ahj.2023.03.012 424. Hijazi Z, Lindbäck J, Alexander JH, Hanna M, Held C, Hylek EM, et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J 2016;37:1582–90. https://doi.org/10. 1093/eurheartj/ehw054 425. Gao X, Cai X, Yang Y, Zhou Y, Zhu W. Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis. Front Cardiovasc Med 2021;8:757087. https://doi.org/10.3389/ fcvm.2021.757087 426. Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol 2015;38:555–61. https://doi.org/10.1002/clc.22435 427. Caldeira D, Costa J, Fernandes RM, Pinto FJ, Ferreira JJ. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol 2014;40:277–84. https://doi.org/10.1007/s10840-014-9930-y 428. Zeng J, Yu P, Cui W, Wang X, Ma J, Zeng C. Comparison of HAS-BLED with other risk models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation: a PRISMA-compliant article. Medicine (Baltimore) 2020;99:e20782. https://doi.org/10. 1097/MD.0000000000020782 429. Wang C, Yu Y, Zhu W, Yu J, Lip GYH, Hong K. Comparing the ORBIT and HAS-BLED bleeding risk scores in anticoagulated atrial fibrillation patients: a systematic review and meta-analysis. Oncotarget 2017;8:109703–11. https://doi.org/10.18632/oncotarget. 19858 430. Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol 2011;90: 1191–200. https://doi.org/10.1007/s00277-011-1267-3 431. Hilkens NA, Algra A, Greving JP. Predicting major bleeding in ischemic stroke patients with atrial fibrillation. Stroke 2017;48:3142–4. https://doi.org/10.1161/STROKEAHA. 117.019183 432. Dalgaard F, Pieper K, Verheugt F, Camm AJ, Fox KA, Kakkar AK, et al. GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study. BMJ Open 2019;9:e033283. https://doi.org/10.1136/bmjopen- 2019-033283 433. Mori N, Sotomi Y, Hirata A, Hirayama A, Sakata Y, Higuchi Y. External validation of the ORBIT bleeding score and the HAS-BLED score in nonvalvular atrial fibrillation patients using direct oral anticoagulants (Asian Data from the DIRECT Registry). Am J Cardiol 2019;124:1044–8. https://doi.org/10.1016/j.amjcard.2019.07.005 434. Yao X, Gersh BJ, Sangaralingham LR, Kent DM, Shah ND, Abraham NS, et al. Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation. Am J Cardiol 2017;120:1549–56. https://doi.org/10. 1016/j.amjcard.2017.07.051 435. Giustozzi M, Proietti G, Becattini C, Roila F, Agnelli G, Mandalà M. ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. Blood Adv 2022;6:4873–83. https://doi.org/10.1182/ bloodadvances.2022008086 436. Shoamanesh A. Anticoagulation in patients with cerebral amyloid angiopathy. Lancet 2023;402:1418–9. https://doi.org/10.1016/S0140-6736(23)02025-1 437. Kurlander JE, Barnes GD, Fisher A, Gonzalez JJ, Helminski D, Saini SD, et al. Association of antisecretory drugs with upper gastrointestinal bleeding in patients using oral anticoagulants: a systematic review and meta-analysis. Am J Med 2022;135:1231–1243.e8. https://doi.org/10.1016/j.amjmed.2022.05.031 438. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 2019;157:403–412.e5. https://doi.org/10.1053/j.gastro.2019.04.041 439. DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005;149:650–6. https://doi.org/10.1016/j.ahj.2004.11.015 440. Harskamp RE, Lucassen WAM, Lopes RD, Himmelreich JCL, Parati G, Weert H. Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial Downloaded from academic.oup.com/eurheartj/article/45/36/3314/7738779 by guest on 07 October 2026